BR0211250A - Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação - Google Patents

Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação

Info

Publication number
BR0211250A
BR0211250A BR0211250-7A BR0211250A BR0211250A BR 0211250 A BR0211250 A BR 0211250A BR 0211250 A BR0211250 A BR 0211250A BR 0211250 A BR0211250 A BR 0211250A
Authority
BR
Brazil
Prior art keywords
formulation
lyophilized
amorphous
stable
preparing
Prior art date
Application number
BR0211250-7A
Other languages
English (en)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven Lamar Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0211250A publication Critical patent/BR0211250A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"FORMULAçãO AMORFA, LIOFILIZADA, ESTáVEL, PARENTERAL, FORMULAçãO FARMACêUTICA, USO DA MESMA, ARTIGO DE MANUFATURA, E, PROCESSO PARA PREPARAR UMA FORMULAçãO". A invenção proporciona uma formulação de olanzapina, liofilizada, amorfa, parenteral.
BR0211250-7A 2001-07-20 2002-07-05 Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação BR0211250A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (1)

Publication Number Publication Date
BR0211250A true BR0211250A (pt) 2004-07-27

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211250-7A BR0211250A (pt) 2001-07-20 2002-07-05 Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação

Country Status (33)

Country Link
US (1) US20040176357A1 (pt)
EP (1) EP1423124B1 (pt)
JP (1) JP2004537546A (pt)
KR (1) KR20040017330A (pt)
CN (1) CN1537007A (pt)
AR (1) AR036180A1 (pt)
AT (1) ATE369137T1 (pt)
AU (1) AU2002320134B2 (pt)
BR (1) BR0211250A (pt)
CA (1) CA2448724A1 (pt)
CO (1) CO5540279A2 (pt)
CY (1) CY1107759T1 (pt)
CZ (1) CZ200484A3 (pt)
DE (1) DE60221674T2 (pt)
DK (1) DK1423124T3 (pt)
EA (1) EA006506B1 (pt)
ES (1) ES2289126T3 (pt)
HK (1) HK1066484A1 (pt)
HR (1) HRP20040037A2 (pt)
HU (1) HUP0401157A3 (pt)
IL (1) IL159098A0 (pt)
MX (1) MXPA04000541A (pt)
MY (1) MY135452A (pt)
NZ (1) NZ529667A (pt)
PE (1) PE20030281A1 (pt)
PL (1) PL366614A1 (pt)
PT (1) PT1423124E (pt)
SI (1) SI1423124T1 (pt)
SK (1) SK182004A3 (pt)
SV (1) SV2003001179A (pt)
UA (1) UA80095C2 (pt)
WO (1) WO2003007912A2 (pt)
ZA (1) ZA200400798B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
JP2021509677A (ja) * 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059947T3 (es) * 1989-09-30 1994-11-16 Eisai Co Ltd Preparados inyectables que contienen cefalosporina y utilizacion de los mismos.
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
HUP0401157A2 (hu) 2004-10-28
PE20030281A1 (es) 2003-03-27
EA200400211A1 (ru) 2004-06-24
HK1066484A1 (en) 2005-03-24
SI1423124T1 (sl) 2008-02-29
ES2289126T3 (es) 2008-02-01
CY1107759T1 (el) 2013-06-19
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
HRP20040037A2 (en) 2004-06-30
SK182004A3 (en) 2004-09-08
PT1423124E (pt) 2007-10-29
EP1423124B1 (en) 2007-08-08
EP1423124A2 (en) 2004-06-02
ZA200400798B (en) 2005-07-27
JP2004537546A (ja) 2004-12-16
CO5540279A2 (es) 2005-07-29
AR036180A1 (es) 2004-08-18
DK1423124T3 (da) 2007-12-03
CN1537007A (zh) 2004-10-13
EA006506B1 (ru) 2005-12-29
PL366614A1 (en) 2005-02-07
KR20040017330A (ko) 2004-02-26
HUP0401157A3 (en) 2008-01-28
WO2003007912A3 (en) 2003-05-01
CA2448724A1 (en) 2003-01-30
NZ529667A (en) 2006-02-24
DE60221674T2 (de) 2008-04-30
WO2003007912A2 (en) 2003-01-30
IL159098A0 (en) 2004-05-12
MXPA04000541A (es) 2004-05-04
CZ200484A3 (cs) 2005-01-12
ATE369137T1 (de) 2007-08-15
DE60221674D1 (de) 2007-09-20
AU2002320134B2 (en) 2007-04-05
UA80095C2 (en) 2007-08-27
US20040176357A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
EE200200130A (et) Uued farmatseutiliste omadustega aminodikarboksüülhappe derivaadid
BRPI0414539A (pt) composto, composição farmacêutica, e, uso de um composto
BR0010659B1 (pt) mÉtodo para a fabricaÇço de artigo absorvente tendo recurso de fixaÇço com pequena auto-adesço.
BR9912109B1 (pt) compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.
CY1108129T1 (el) Παραγωγα 4-αμινο-6-φαινυλ-πυρρολο[2,3-δ]πυριμιδινης
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
CY1113047T1 (el) Νεα κρυσταλλικη και αμορφη μορφη μιας ενωσης τριαζολο (4,5-d) πυριμιδινης
BR9909925B1 (pt) derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina.
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
SE9904505D0 (sv) Novel compounds
BR0208338A (pt) Derivados de piridina
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
EA200200954A1 (ru) Композиция
SE0101932D0 (sv) Pharmaceutical combinations
BR0211250A (pt) Formulação amorfa, liofilizada, estável, parenteral, formulação farmacêutica, uso da mesma, artigo de manufatura, e, processo para preparar uma formulação
ITUD20000163A0 (it) Dispositivo per la produzione di manufatti poliuretanici, relativo procedimento e manufatti poliuretanici cosi' ottenuti
BR9808770A (pt) Conjugado medicamentoso, método para suaprodução e seu uso
BR0015630B1 (pt) material refratÁrio isolante, artigo, e, composiÇço aquosa para a fabricaÇço de um material refratÁrio isolante.
SE0003476D0 (sv) Compounds
BR0212772A (pt) Processo para a preparação de repaglinida
PT1362040E (pt) Processo para a preparacao de mesilatos de derivados de piperazina
UA83266C2 (en) Oxazole derivatives of tetracyclines
DE50111509D1 (de) Für pharmazeutische Anwendungen dienender Spritzling
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A A NUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.